Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy-Reference-Cited by-同舟云学术

Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy

Published:2018 Issue:1 Volume:3 Page:73-88
ISSN:2058-9689
Container-title:Molecular Systems Design & Engineering
language:en
Short-container-title:Mol. Syst. Des. Eng.

Author:

Khera Eshita¹²³⁴,Cilliers Cornelius¹²³⁴,Bhatnagar Sumit¹²³⁴,Thurber Greg M.¹²³⁴⁵^ORCID

Affiliation:

1. Department of Chemical Engineering

2. University of Michigan

3. Ann Arbor

4. USA

5. Department of Biomedical Engineering

Abstract

A computational model predicting bystander payload distribution as a function of controllable design parameters for guiding efficient clinical ADC development.

Funder

Division of Chemical, Bioengineering, Environmental, and Transport Systems

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,Industrial and Manufacturing Engineering,Process Chemistry and Technology,Energy Engineering and Power Technology,Biomedical Engineering,Chemical Engineering (miscellaneous),Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2018/ME/C7ME00093F

Reference83 articles.

1. Expanding the Reach of Antibody–Drug Conjugates

2. Antibody Drug Conjugates for Cancer Therapy

3. Strategies and challenges for the next generation of antibody–drug conjugates

4. Antibodies to watch in 2016

5. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-21

2. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data;Science Advances;2024-05-31

3. In vivoAuto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies;2024-04-10

4. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression;CPT: Pharmacometrics & Systems Pharmacology;2024-03-26

5. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer;Expert Opinion on Drug Metabolism & Toxicology;2024-01-12